This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
HAMBURG, Germany, Oct. 4, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that Dr. Werner Lanthaler, CEO of Evotec, will temporarily stand down from his role within the company due to health reasons.
Dr. Lanthaler informed the Supervisory Board of his situation. The Supervisory Board has approved his leave of absence and whishes Dr. Lanthaler an early recovery. Following a decision of the Supervisory Board after consulting Dr. Lanthaler, the Management Board of Dr. Cord Dohrmann (CSO) and Colin Bond (CFO) under the direction of Dr. Mario Polywka, the Chief Operating Officer, will lead the company in the absence of Dr. Lanthaler.
Dr. Werner Lanthaler will reassume the role of CEO as soon as he has recovered.
About Evotec AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Medimmune/AstraZeneca, and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in the field of Alzheimer's disease. For additional information please go to
FORWARD LOOKING STATEMENTS— Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
CONTACT: Dr Mario Polywka
Chief Operating Officer
+44.(0)1235.44 16 76
+44.(0)7771.95 41 90 Fax
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Deutschland)